TDC
EIDX

Thompson Davis & Co’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Thompson Davis & Co’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$5K Sell
475
-525
-53% -$8.63K 0.01% 588
2018
Q2 		$20K Buy
+1,000
New +$21K 0.05% 315

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Thompson Davis & Co's EIDX Position: Q3 2018 in Review

Thompson Davis & Co reduced its Eidos Therapeutics, Inc. Common Stock (EIDX) stake by 53% in Q3 2018, selling an estimated $8.63K and leaving 475 shares worth $5K. The position accounts for 0.01% of the portfolio, ranked #588.

Thompson Davis & Co first reported a position in EIDX in Q2 2018 and has held it in 2 quarters since. The position peaked at $20K in Q2 2018. 58 funds tracked by Wall St. Rank hold EIDX as of Q3 2018.

  • Thompson Davis & Co held 475 shares of Eidos Therapeutics, Inc. Common Stock worth $5K as of Q3 2018.
  • Thompson Davis & Co sold 525 Eidos Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $8.63K.
  • Eidos Therapeutics, Inc. Common Stock made up 0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #588 holding.
  • Thompson Davis & Co first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and has held it in 2 quarters since.
  • Thompson Davis & Co's Eidos Therapeutics, Inc. Common Stock position peaked at $20K in Q2 2018.
  • 58 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.